| scholarly article | Q13442814 |
| P2093 | author name string | Mark Johnson | |
| Simon J Cook | |||
| Annette S Gillings | |||
| Ceri M Wiggins | |||
| Kathryn Balmanno | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function | Q24293924 | ||
| Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak | Q24296478 | ||
| ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL | Q24306894 | ||
| RACK1 and CIS mediate the degradation of BimEL in cancer cells | Q24322936 | ||
| Bim: a novel member of the Bcl-2 family that promotes apoptosis | Q24532974 | ||
| JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis | Q24554008 | ||
| The Bcl-2 apoptotic switch in cancer development and therapy | Q24620437 | ||
| Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation | Q24655658 | ||
| Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. | Q27824789 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines | Q39819940 | ||
| Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 | ||
| BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. | Q39907753 | ||
| Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. | Q39977634 | ||
| Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion | Q40033557 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. | Q40102679 | ||
| Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines | Q40126011 | ||
| Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia | Q40131183 | ||
| Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. | Q40323778 | ||
| Identification of a DEF-type docking domain for extracellular signal-regulated kinases 1/2 that directs phosphorylation and turnover of the BH3-only protein BimEL. | Q40454938 | ||
| Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors | Q40540288 | ||
| Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover | Q40606380 | ||
| Role of Bim in the survival pathway induced by Raf in epithelial cells | Q40607194 | ||
| Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. | Q40626751 | ||
| Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. | Q40662652 | ||
| Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways | Q40666435 | ||
| Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. | Q41836780 | ||
| FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons | Q42918105 | ||
| c-Cbl is not required for ERK1/2-dependent degradation of BimEL. | Q43098314 | ||
| Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 | ||
| Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. | Q46757499 | ||
| Mutant B-RAF mediates resistance to anoikis via Bad and Bim. | Q46774780 | ||
| Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition | Q50335943 | ||
| Drivers and passengers | Q59080774 | ||
| Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity | Q28138855 | ||
| Molecular cloning and characterization of six novel isoforms of human Bim, a member of the proapoptotic Bcl‐2 family1 | Q28208950 | ||
| Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB | Q28306356 | ||
| betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis | Q28306984 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics | Q28469345 | ||
| Androgen-dependent apoptosis in male germ cells is regulated through the proto-oncoprotein Cbl | Q28564996 | ||
| Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release | Q28567073 | ||
| BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations | Q28756824 | ||
| The BCL-2 protein family: opposing activities that mediate cell death | Q29547380 | ||
| Targeting cancer with small molecule kinase inhibitors | Q29547395 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| FOXOs, cancer and regulation of apoptosis | Q33642512 | ||
| Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. | Q35022505 | ||
| Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. | Q35075545 | ||
| MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825 | Q35804449 | ||
| Intrinsic tumour suppression | Q35953133 | ||
| MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism | Q35990714 | ||
| Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas | Q36026392 | ||
| Promoting apoptosis as a strategy for cancer drug discovery | Q36292878 | ||
| ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation | Q36647913 | ||
| Multisite phosphorylation regulates Bim stability and apoptotic activity | Q36756298 | ||
| Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate | Q36787540 | ||
| Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic | Q36945203 | ||
| Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels | Q36946423 | ||
| The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias | Q36967858 | ||
| Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival | Q37028555 | ||
| Oncogene addiction | Q37152445 | ||
| Bcl-2 inhibitors: small molecules with a big impact on cancer therapy | Q37275477 | ||
| Tumour cell survival signalling by the ERK1/2 pathway | Q37290943 | ||
| Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics | Q37431491 | ||
| Bim is a suppressor of Myc-induced mouse B cell leukemia | Q37647369 | ||
| Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. | Q38338829 | ||
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer | Q38445646 | ||
| Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors | Q39457731 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autophagy | Q288322 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 6050-6062 | |
| P577 | publication date | 2009-09-29 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | FEBS Journal | Q1388041 |
| P1476 | title | Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics | |
| P478 | volume | 276 |
| Q34398390 | A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis |
| Q34786462 | Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells |
| Q46558378 | Application of quality-by-design approach to optimize diallyl disulfide-loaded solid lipid nanoparticles. |
| Q37317126 | BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia |
| Q33642685 | BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine |
| Q32178159 | Bauerenol, a triterpenoid from Indian Suregada angustifolia: Induces reactive oxygen species-mediated P38MAPK activation and apoptosis in human hepatocellular carcinoma (HepG2) cells |
| Q64286890 | Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer |
| Q35353981 | Bim contributes to phenethyl isothiocyanate‐induced apoptosis in breast cancer cells |
| Q33760917 | Bryostatin analogue-induced apoptosis in mantle cell lymphoma cell lines |
| Q36170136 | CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies |
| Q39803115 | Camptothecin Induces Apoptosis of Human Retinoblastoma Cells via Activation of FOXO1 |
| Q34003160 | Cell death and inflammatory bowel diseases: apoptosis, necrosis, and autophagy in the intestinal epithelium |
| Q37412481 | Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway |
| Q36425775 | Chloroquine inhibits hepatocellular carcinoma cell growth in vitro and in vivo |
| Q48356930 | Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer. |
| Q34168653 | Critical Role of p53 Upregulated Modulator of Apoptosis in Benzyl Isothiocyanate-Induced Apoptotic Cell Death |
| Q39091696 | Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation |
| Q38704670 | Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models |
| Q58612606 | Egr-1 is involved in coronary microembolization-induced myocardial injury via Bim/Beclin-1 pathway-mediated autophagy inhibition and apoptosis activation |
| Q41491478 | Etlingera elatior Extract promotes cell death in B16 melanoma cells via down-regulation of ERK and Akt signaling pathways |
| Q39437671 | Flavokawain B induces apoptosis of human oral adenoid cystic cancer ACC-2 cells via up-regulation of Bim and down-regulation of Bcl-2 expression |
| Q41209642 | Fork Head Box Class O1 (FOXO1) Activates Bim Expression to Mediate Cardiac Apoptosis in Chronic Intermittent Hypoxia-Induced Cardiac Hypertrophy |
| Q43572027 | H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib |
| Q36092925 | Identification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways |
| Q38850384 | Identification of novel target genes specifically activated by deregulated E2F in human normal fibroblasts. |
| Q35312641 | Increased expression of the pro-apoptotic protein BIM, a mechanism for cAMP/protein kinase A (PKA)-induced apoptosis of immature T cells. |
| Q47563196 | Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway |
| Q35845241 | Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma |
| Q39143004 | Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine |
| Q35776414 | KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells |
| Q37500162 | Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma |
| Q92114330 | LncRNA SNHG6 functions as a ceRNA to regulate neuronal cell apoptosis by modulating miR-181c-5p/BIM signalling in ischaemic stroke |
| Q36850845 | MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor |
| Q42019758 | MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. |
| Q38007869 | Mechanisms of acquired resistance to ERK1/2 pathway inhibitors |
| Q89142802 | Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer |
| Q41830027 | Methylsulfonylmethane Induces p53 Independent Apoptosis in HCT-116 Colon Cancer Cells |
| Q36602853 | MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies |
| Q36014262 | Mir-192 suppresses apoptosis and promotes proliferation in esophageal aquamous cell caicinoma by targeting Bim. |
| Q38105962 | New molecular insights into osteosarcoma targeted therapy |
| Q35234806 | Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation |
| Q35723911 | Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells |
| Q28534817 | Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells |
| Q51053600 | RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies |
| Q35083742 | Regulation and Function of the RasGRP Family of Ras Activators in Blood Cells |
| Q26781203 | Regulation of Bim in Health and Disease |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q47679039 | Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells |
| Q39186523 | Studying the protein expression in human B lymphoblastoid cells exposed to 1.8-GHz (GSM) radiofrequency radiation (RFR) with protein microarray |
| Q30303153 | Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia |
| Q59136532 | Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors |
| Q47632574 | Synthesis and inhibitory effect of 10-chlorocanthin-6-one on ovarian cancer HO8910PM cells |
| Q36546429 | Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q39227285 | The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance |
| Q87691736 | The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer |
| Q37649732 | The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells |
| Q38987491 | The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells. |
| Q44392521 | The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma |
| Q132730932 | The myeloma bone marrow environment and survival signaling |
| Q36427377 | The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q28534603 | Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple Myeloma |
| Q34345253 | Transcriptome profiling of CTLs regulated by rapamycin using RNA-Seq |
| Q38466630 | Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. |
| Q39273438 | miR-17-5p Inhibitor Enhances Chemosensitivity to Gemcitabine Via Upregulating Bim Expression in Pancreatic Cancer Cells |
| Q39020350 | miR-181a mediates TGF-β-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer |
| Q39480964 | miR‐92 is a key oncogenic component of the miR‐17–92 cluster in colon cancer |
Search more.